

PCTWORLD INTELLECT
Inte

INTERNATIONAL APPLICATION PUBLISHED



WO 9603426A1

(51) International Patent Classification 6 :

C07K 1/32, 14/765

A1

(43) International Publication Date: 8 February 1996 (08.02.96)

(21) International Application Number: PCT/US95/08479

(22) International Filing Date: 7 July 1995 (07.07.95)

(30) Priority Data:
279,371 22 July 1994 (22.07.94) US

(71) Applicant: DUKE UNIVERSITY [US/US]; 001 Allen Building, Durham, NC 27706 (US).

(72) Inventor: BONAVENTURA, Joseph; 127 Circle Drive, Beaufort, NC 28516 (US).

(74) Agents: FLINTOFT, Gerald, G. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: HUMAN SERUM ALBUMIN-PORPHYRIN COMPLEXES WITH THE ABILITY TO BIND OXYGEN AND THERAPEUTIC USES THEREOF

(57) Abstract

The invention is directed to human serum albumin-porphyrin (HSA-P) complexes which are capable of reversible oxygen binding and their uses. These complexes may be used in applications requiring physiological oxygen carriers such as in blood substitute solutions, or in applications requiring plasma expanders. Methods for the production of these complexes are provided. In a specific example, HSA-P complexes are shown to exhibit reversible oxygen binding. In another example, the HSA-P complex does not exhibit appreciable vasoactivity.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LJ	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

HUMAN SERUM ALBUMIN-PORPHYRIN COMPLEXES WITH THE ABILITY TO BIND OXYGEN AND THERAPEUTIC USES THEREOF

1. INTRODUCTION

5 The present invention is directed to human serum
albumin (HSA)-porphyrin complexes, and their
production and uses. Human serum albumin-porphyrins
(HSA-P) produced by methods of the present invention
10 may be used in applications requiring physiological
oxygen carriers such as in blood substitute solutions,
or in applications requiring plasma expanders.

2. BACKGROUND OF THE INVENTION

15 2.1 BLOOD SUBSTITUTES

Treatment of many clinical conditions involving
blood loss or blood deficiency requires
supplementation with a source of donor blood or a
20 blood substitute. A primary goal is to restore the
circulation of oxygen through the body, a function
that is physiologically mediated by the hemoglobin
found in red blood cells.

Transfusion of a patient with donated blood,
25 while used widely, has a number of disadvantages.
Firstly, there may be a shortage of a patient's blood
type. Secondly, transfused blood may be contaminated
with infectious agents such as hepatitis viruses,
cytomegaloviruses, Epstein-Barr virus, serum
30 parvoviruses, syphilis, malaria, filariasis,
trypanosomiasis, babesiosis, pathogenic bacteria, and
HIV (Bove, Progr. Hematol. 14: 123-145, 1986).
Thirdly, donated blood has a limited shelf life.

An alternative to transfused blood involves the
35 use of blood substitutes. A blood substitute is an
oxygen carrying solution that also provides the

oncotic pressure necessary to maintain blood volume. Two types of blood substitutes have recently been studied, fluorocarbon emulsions and hemoglobin solutions.

5 Fluorocarbon emulsions, however, are not feasible blood substitutes, since they are known at times to block the immune system (Dellacherie, Crit. Rev. Ther. Drug Carriers 3:41-94, 1986). In addition, the use of
10 fluorocarbons is limited to situations in which high partial pressures of oxygen can be administered. They do not have a sufficiently high oxygen binding capacity for use under normal physiological conditions.

Native isolated hemoglobin, when used as a blood
15 substitute, has a number of disadvantages. Firstly, large dosages are required (Walder, Biotech '88, San Francisco, Nov. 14-16, 1988). A single unit (450 ml) of a 10% hemoglobin solution contains 45 g of protein. Since it is estimated that ten million units of blood
20 are used in the U.S. per year, the production of 450,000 kg of hemoglobin would be required. Secondly, as cited previously, the potential exists for contamination of the isolated hemoglobin by any number of infectious agents. Thirdly, although hemoglobin is
25 normally a tetramer of 64,000 molecular weight, it can dissociate to form alpha-beta dimers which are rapidly cleared by the kidneys, therefore lowering the effective residence time of functional hemoglobin in the body. Fourthly, cell-free hemoglobin has too high
30 an oxygen affinity to effectively release oxygen to the tissues due to the absence of 2,3 diphosphoglycerate (2,3 DPG). Efforts to restore 2,3 DPG have been unsuccessful since 2,3 DPG is rapidly cleared from the circulation (Snyder and Walder,
35 *Chemically Modified and Recombinant Hemoglobin Blood

Substitutes" in Biotechnology of Blood, Butterworth-Heinemann, pages 101-116, 1991). Finally, cell-free hemoglobin has been shown to act as a scavenger of nitric oxide in the body, a property which results in a vasoconstrictive effect on blood vessels (Kilbourn, R., et al., Biochem. Biophys. Res. Comm. 199:155-162, 1994). This vasoactivity may compromise the utility of cell-free hemoglobin in certain clinical conditions.

10

2.2 HUMAN SERUM ALBUMIN

Human serum albumin, a protein of 585 amino acids with a molecular weight of 66,500 daltons, is the most abundant protein in human plasma. It comprises 60% of the total protein, with a normal concentration of 42 g/liter. It provides 80% of the osmotic pressure of blood, and is a very stable and soluble protein. It serves as a transport carrier for a variety of ligands, including fatty acids, amino acids, steroids, ions, and pharmaceuticals. It is able to shepherd hydrophobic ligands throughout the body. It was one of the first proteins to be crystallized, and the standard purification protocol was developed by Cohn in 1946 (Peters, "Serum Albumin", in Advances in Protein Chemistry, Academic Press, 1985).

The three-dimensional structure of human serum albumin was determined by X-ray crystallography to a resolution of 2.8 Å. Three homologous domains were identified and the principal ligand binding sites were localized (He and Carter, Nature 358:209-215, 1992; Carter and Ho, Adv. Protein Chem. 45:153-203, 1994).

2.3 HEME

Heme is a porphyrin in which a central iron atom is coordinately bound to the four pyrrole nitrogen

atoms of the porphyrin ring. The physiological oxygen carriers, hemoglobin and myoglobin, contain a heme moiety that is the site of oxygen binding. Oxygen binds to the iron atom of free heme; however, only the
5 ferrous (FeII) form of heme can bind oxygen. The binding of oxygen can rapidly lead to oxidation of the iron atom, creating ferric (FeIII) heme, which cannot bind oxygen. This oxidation reaction, therefore, has to be circumvented in order to optimize the capacity
10 of the heme to reversibly bind oxygen for long periods. The three dimensional structure of the polypeptide moieties of myoglobin and hemoglobin result in a protective enclosure for the heme. This structure prevents the oxidation reaction which would
15 occur upon the binding of oxygen by preventing the formation of an intermediate in this reaction, a sandwich dimer of two hemes with oxygen. Thus, the design of these molecules maximizes the oxygen binding capability of their heme moieties (Stryer,
20 Biochemistry, Chapter 4, pp. 65-85, W.H. Freeman and Co., New York, 1981).

Efforts to modify hemes in order to design compounds which mimic the oxygen binding potential of the native heme in its hemoglobin or myoglobin pocket
25 have resulted in the development of many porphyrin derivatives that have been tested for their ability to bind oxygen and exhibit resistance to oxidation (Traylor and Traylor, Ann. Rev. Biophys. Bioeng. 11:105-127, 1982). Such porphyrin derivatives include
30 capped porphyrins (Almog et al., J. Am. Chem. Soc. 97:226-227, 1975; Rose et al., Proc. Natl. Acad. Sci. 79:5742-5745, 1982) and basket-handle porphyrins (Lexa et al., J. Am. Chem. Soc. 106:4755-4765, 1984)

Picket fence porphyrin is such a modified heme.
35 It was designed as a model compound to mimic the

oxygen binding site of myoglobin and hemoglobin. Four axial bases are covalently attached to the porphyrin ring, effectively creating a protective enclosure for bound oxygen due to the great steric bulk provided (Collman et al., Proc. Natl. Acad. Sci. 75:1052-1055, 1978). When oxygen binds to the iron atom, five of the six coordination positions of this molecule are then occupied. As a result, formation of the intermediate in the oxidation reaction is prevented by the steric design of the molecule, and oxidation is prevented. Efforts to optimize the picket-fence structure currently continue through the use of molecular modeling (Wuenschel et al., J. Am. Chem. Soc. 114:3346-3355, 1992).

Liposome-bound picket fence porphyrins were shown to bind CO with high affinity, but were subject to autoxidation, and no stable oxygenated forms were observed (Makino et al., Biochem. and Biophys. Res. Comm. 108:1010-1015, 1982); these complexes were later shown to reversibly bind oxygen (Tsuchida et al., J. Chem. Soc. Dalton Trans., p. 1147-1151, 1984).

2.4 ALBUMIN/PORPHYRINS

Human serum albumin normally binds free heme in the body (heme-HSA); it acts as a scavenger for surplus heme released in hemorrhagic conditions. The complex heme-HSA normally oxidizes to metheme-HSA. The resultant complex, methemalbumin, can be diagnostic for internal hemorrhage (Peters, *supra*).

Albumin, with its known affinity for porphyrins, has been studied to determine the effectiveness of this protein carrier for the delivery of hydroxyethyl vinyl deuteroporphyrin and irreversible porphyrin aggregates in photodynamic therapy of tumors (Cohen and Margalit, J. Biochem. 270:325-330, 1990). Certain

albumin-porphyrin compounds have also been developed as anti-HIV agents, in which the porphyrin derivatives include hemin, proto-porphyrin, meso-porphyrin, iron meso-porphrin, hemato-porphyrin, iron hemato-porphyrin, deuterio-porphyrin copper chlorophyllin (International Publication No. WO 9303035 published February 18, 1993).

Heme-HSA has never been shown to reversibly bind oxygen. The heme moiety is presumably not configured into the protein in such a way that it is shielded from the oxidation reaction that would occur if oxygen binds.

However, optimization of human serum albumin as an oxygen carrier is provided by the HSA-porphyrin compounds of the present invention, in which formation of a complex between HSA and a suitable oxygen-binding moiety produces a mobile oxygen carrier which reversibly binds oxygen and thus can be used as a blood substitute.

3. SUMMARY OF THE INVENTION

The invention is directed to compositions comprising human serum albumin-porphyrin (HSA-P) complexes, methods for their production, and the use of these molecules as blood substitutes. The various porphyrins provided by the invention can bind oxygen reversibly, and they can be used to transport and deliver oxygen when bound to an HSA carrier. The invention further provides HSA-P complexes which do not exhibit vasoactivity. The invention also provides various modified porphyrins, including picket-fence porphyrin, as the oxygen-binding moiety in the HSA-P complex.

The invention is illustrated by means of examples in which methods are given for the synthesis of HSA-P, and by examples in which the oxygen-carrying capacity of the HSA-P is demonstrated, and by an example in which the lack of vasoactivity of the HSA-P of the present invention is illustrated.

4. BRIEF DESCRIPTION OF THE FIGURES

Figure 1. Structure of picket fence porphyrin #1: Fe meso-tetra (a,a,a,a-pivalamido-phenyl) porphine.

Figure 2. Structure of picket fence porphyrin #2: Fe meso-tetra (a,a,a,o-pivalamido-phenyl) porphine.

Figure 3. Absorption spectra of HSA-PFP #1 in the wavelength region from 450 to 700 nm. Optical pathlength was 1 cm. The solvent was DMSO made 1 Mm in M-methylimidazole. The nominal concentration of #1 was 55 μ M.

Figure 4. Absorption spectra of the various forms of the HSA-PFP #1 with human serum albumin. Curve 1 corresponds to the carbon monoxide derivative; curve 2 to the oxygenated derivative and curve 3, the deoxygenated derivative. The pathlength was 1 cm.

Figure 5. Absorption spectra showing the raw data from an oxygen equilibrium experiment with 5 μ M HSA-PFP #1 complex. The complex was in 50 Mm Bis-Tris, pH 7.0 at 20°C. The deoxygenated derivative has the highest molar absorptivity at 422 nm and the oxygenated derivative has the lowest absorptivity at 422 nm. Each intermediate spectrum corresponds to the

partially oxygenated derivative at different oxygen concentrations.

Figure 6. The percent oxygen saturation of human
5 hemoglobin A and HSA-PFP #1 as a function of oxygen
concentration (pO_2 in mm Hg) is shown. —□— HSA-PFP#1;
—◆—: hemoglobin A.

Figure 7. Hill plots for 5 mM HSA-PFP #1 and
10 human hemoglobin A in 50 mM Bis-Tris, pH 7.0 at 20°C
using data derived from Figure 6. —□— HSA-PFP#1;
—◆—: hemoglobin A.

Figure 8. (a-d) Absorption spectra of HSA-PFP #2
15 cycling between the oxygenated (O_2) (1) and
deoxygenated (N_2) (2) derivatives.

Figure 9. Effects of bovine cell-free hemoglobin
(Hgb), picket-fence porphyrin human serum albumin
20 (HSA-PFP) (#1) and heme-HSA in the concentration-
contraction curves evoked by phenylephrine in rat
aorta ring with endothelium, incubated for 4 hours in
culture medium containing endotoxin (LPS), 200 ng/ml.
Results are presented as mean \pm SEM of 4 different
25 experiments. —□—: LPS treated; —▲—: LPS + 10 μ l/ml
hemoglobin; —○— LPS + 20 μ l/ml HSA-PFP#2; —▽—: LPS
+ 20 μ l/ml HSA-heme.

5. DETAILED DESCRIPTION OF THE INVENTION

30

The invention is directed to compositions
comprising human serum albumin-porphyrin (HSA-P)
complexes, methods for their production, and the use
of these molecules as blood substitutes. The various
35 porphyrins provided by the invention can bind oxygen

reversibly, and they can be used to transport and deliver oxygen when bound to an HSA carrier. The invention further provides HSA-P complexes which do not exhibit vasoactivity. The invention also provides
5 various modified porphyrins, including picket-fence porphyrin, as the oxygen-binding moiety in the HSA-P complex.

The invention is illustrated by means of examples in which methods are given for the synthesis of HSA-P
10 complexes, and by examples in which the oxygen-carrying capacity of the HSA-P complexes is demonstrated, and by an example in which the lack of vasoactivity of the HSA-P complexes of the present invention is illustrated.

15

5.1 Preparation of HSA-P

The invention provides human serum albumin-porphyrin (HSA-P) complexes. These are hybrid molecules that complex HSA with an oxygen-binding
20 moiety. These HSA-P complexes provide several advantages over the prior art. First, the biocompatibility of human serum albumin (which is already used as a plasma expander and resuscitation fluid) allows the HSA-P complex to readily transport
25 to and access numerous tissues and organs. Secondly, in a HSA-P complex preferred for use, such HSA-P complex does not have the vasoconstrictive potential of hemoglobin, i.e., the HSA-P complex does not promote high blood pressure. It is shown herein that
30 an HSA-P complex does not have the vasoconstrictive potential of hemoglobin (Example 10, *infra*), a side effect which can limit its clinical effectiveness.

Thus, in a preferred aspect, the invention provides for HSA-P complexes which are capable of

35


reversible cycles of oxygenation and deoxygenation, and which does not exhibit significant vasoactivity.

HSA-P complexes of the present invention may be screened for oxygen binding by any method known in the art, e.g., tonometry (Riggs and Wolbach, J. Gen. Physiol. 39:585-605, 1956) (see Example 7, infra) in order to determine the degree of saturation of the porphyrin moiety as a function of the oxygen partial pressure. This data can be extrapolated to a Hill Plot which allows for an assessment of the cooperativity of oxygen binding.

HSA-P complexes of the present invention may be screened for reversibility of the oxygen binding by any method known in the art, e.g., spectrophotometrically by successive cycles of incubation with oxygen, followed by repeated vacuum evacuations with nitrogen purges (see Example 8, infra). Characteristic changes in absorption that indicate oxy- and deoxy- complexes at a particular wavelength may be used to determine the potential of an HSA-P for use as an oxygen carrier.

In a preferred embodiment, the porphyrin in the HSA-P complex is picket fence porphyrin (PFP). As described in Section 2 above, PFP is a modified heme. By virtue of its structure, this molecule can be used to provide an oxygen-binding moiety to an exogenous protein.

A HSA-P complex of the invention is that containing a PFP that is a compound of the following formula:



25 wherein

M is Co, Fe, or Mn;

R^1 is $C(CH_3)_3$, or $(CH_2)_n C_6H_4 R^2$;

R^2 is H, CN, NO_2 , CO-phenyl, halogen, CF_3 , $NHCOR^3$, CO_2R^3 , OR^3 , $SO_2N(R^3)_2$, NR^4R^5 , or SO_2R^6 ;

30 R^3 is H, C_1-C_6 alkyl or phenyl;

R^4 and R^5 , independently are H or C_1-C_4 alkyl;

R^6 is C_1-C_6 alkyl or phenyl; and

n is 0-8.

The invention provides various picket fence
 35 porphyrins that retain an oxygen binding capacity and

are capable of binding the human serum albumin and serving as a mobile oxygen carrier.

Human serum albumin may be prepared by any method known in the art such as purification from a natural
5 source (including purification by polyacrylamide gel electrophoresis, immunoprecipitation or affinity chromatography), chemical synthesis, and recombinant DNA technology. The technique of Cohn involving
10 successive cycles of precipitation from plasma to yield the 98% pure Fraction V albumin may be employed (Cohn et al., J. Am. Chem. Soc. 68:459-475, 1946). Recombinant DNA techniques may be used with the cloned
15 gene (Hawkins and Dugaiczky, Gene 19: 55-58, 1982) to express the recombinant protein in bacteria or any of other known expression systems in the art (see Current
20 Protocols in Molecular Biology, Ausubel, F., et al., eds., Wiley and Sons, 1987). Alternatively, the protein may be purchased from known suppliers including Cutter Laboratories (Dallas, Texas), Abbott
Laboratories (North Chicago, Illinois), and Sigma
Chemical Company (St. Louis, Missouri).

The porphyrins in the HSA-P complexes of the instant invention may be made by methods previously described (Collman et al., J. Am. Chem. Soc. 97:1427-
25 1439, 1975). Condensation of the appropriately substituted nitrobenzaldehyde with pyrrole yields a tetra-(nitrophenyl)porphyrin. Reduction of the nitro group using excess tin chloride in concentrated mineral acid yields the corresponding amine.
30 Condensation of the tetra-amine with the appropriate acid chloride affords the substituted porphyrins of the instant invention. The requisite acid chlorides are either commercially available (Aldrich Chemical Co.) or can be made by standard methods from the
35 corresponding carboxylic acids and thionyl chloride.

Standard protecting groups may be necessary to prepare some of the requisite acid chlorides. Removal of the protecting groups can be affected under standard conditions following condensation of the amine with
5 acid chloride.

HSA-P complexes derivatives may be prepared by reacting a porphyrin, in a specific embodiment a picket-fence porphyrin, with carbon monoxide (CO) to form CO-PFP. This complex is then further reduced
10 with dithionite. The CO-PFP is then mixed with HSA, and formation of a complex with HSA can be assessed by chromatography and ultrafiltration. Removal of the CO is accomplished by illumination of the sample with light in a tonometer with oxygen, yielding an O₂-HSA-
15 PFP complex. The oxygen can be removed with nitrogen, leaving the HSA-PFP complex.

The invention also provides for HSA-P complexes in which the HSA is in the form of multimers, which in a preferred embodiment may be a dimer formed by the
20 creation of a disulfide bond between HSA monomers, and which may prevent extravasation of the HSA-P from the circulation. Such dimers can be formed by the addition of mercuric chloride to a solution of HSA monomers, which causes the thiol-containing albumin to
25 dimerize through a mercury bridge (Hughes and Dintzis, J. Biol. Chem. 239:845-849, 1964). Subsequent oxidation of this HSA dimer by treatment with iodine results in a formation of a disulfide bond between the cysteines to form a disulfide dimer (Straessle, J. Am.
30 Chem. Soc. 76:3138-3142, 1954). HSA disulfide dimers may also be prepared by oxidation of HSA monomers with ferricyanide (Andersson, Biochem. et Biophys. Acta 117:115-133, 1966) or by oxidation at alkaline pH in the presence of oxygen. HSA multimers of the instant
35 invention can also be prepared by crosslinking with

any of known reagents in the art, including carbodiimide and glutaraldehyde.

HSA-P complexes of the present invention may be screened for oxygen binding by any method known in the art, e.g., tonometry (Riggs and Wolbach, J. Gen. Physiol. 39:585-605, 1956) (see Example 7, infra) in order to determine the degree of saturation of the porphyrin moiety as a function of the oxygen partial pressure. This data can be extrapolated to a Hill Plot which allows for an assessment of the cooperativity of oxygen binding.

HSA-porphyrins of the present invention may be screened for reversibility of the oxygen binding by any method known in the art, e.g., spectrophotometrically by successive cycles of incubation with oxygen, followed by repeated vacuum evacuations with nitrogen purges (see Example 8, infra). Characteristic changes in absorption that indicate oxy- and deoxy- complexes at a particular wavelength may be used to determine the potential of an HSA-P complex for use as an oxygen carrier.

HSA-porphyrins of the present invention may be screened for vasoactivity by any method known to those skilled in the art, including but not limited to the use of in vitro models such as the phenylephrine-evoked contraction of endothelium (See Example 10, infra).

5.2. Utilities of the Invention

The HSA-P compositions of the present invention may be used as blood substitutes or as a blood plasma expander, in a pharmaceutical composition with an acceptable carrier, and with other plasma expanders, or in any application where a physiological oxygen carrier is needed. The pharmaceutical carriers may be

such physiologically compatible buffers as Hank's or Ringer's solution, physiological saline, a mixture consisting of saline and glucose, and heparinized sodium-citrate-citrate acid-dextrose solution. The

- 5 HSA-P complexes produced by the methods of the present invention can be mixed with colloidal-like plasma substitutes and plasma expanders such as linear polysaccharides (e.g., dextran), hydroxyethyl starch, balanced fluid gelatin, and other plasma proteins.
- 10 Additionally, the HSA-PFP may be mixed with water soluble, physiologically acceptable, polymeric plasma substitutes, examples of which include polyvinyl alcohol, poly (ethylene oxide), polyvinylpyrrolidone, and ethylene oxide-polypropylene glycol condensates.
- 15 Techniques and formulations for administering the compositions comprising the HSA-P complexes generally may be found in Remington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA, latest edition.

- Pharmaceutical compositions for use in accordance
- 20 with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers or excipients.

- The compounds may be formulated for administration by injection, e.g., by bolus injection
- 25 or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous
- 30 vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal
5 or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration.

Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical
10 procedures in cell cultures or experimental animals, e.g., for determining the LD_{50} (the dose lethal to 50% of the population) and the ED_{50} (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects
15 is the therapeutic index and it can be expressed as the ratio LD_{50}/ED_{50} . Compounds which exhibit large therapeutic indices are preferred.

The data obtained from animal studies can be used in formulating a range of dosage for use in humans.
20 The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED_{50} with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
25 For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC_{50}
30 (i.e., the concentration of the test compound which achieves a half-maximal inhibition of symptoms). Such information can be used to more accurately determine useful doses in humans.

Subjects for treatment with the compounds of the
35 present invention include humans and other mammals

such as monkeys, chimpanzees, rodents, pigs, cows, horses, dogs, cats, and particularly primates.

6. EXAMPLE: PREPARATION OF HUMAN SERUM ALBUMIN-PICKET FENCE PORPHYRINS

5

A 500 μ M stock solution of Fe meso-tetra (a,a,a,a-pivalamido-phenyl) porphine (PFP #1) (Figure 1) or Fe meso-tetra (a,a,a,o-pivalamido-phenyl) porphine (PFP#2) (Figure 2) (both purchased from
10 Porphyrin Products, Provo, Utah) was prepared in 100% dimethyl sulfoxide (DMSO) containing 1 mM N-methylimidazole.

The spectrum of this material (60 μ M) (PFP#2) after degassing, is shown in Figure 3, spectrum 1.
15 Addition of carbon monoxide (CO) results in spectrum 2, indicating that the PFP is partially reduced (Fe^{2+}). Addition of dithionite further reduces the PFP (spectrum 3). The CO-PFP was mixed with HSA (Albumin-
20 USP 25%; Cutter Pharmaceuticals, Dallas, Texas) in 50 mM Bis-Tris pH 7 (3 ml PFP (60 μ M) with 7.5 ml HSA (14.5 μ M); measured PFP/HSA ratio (Fe/protein) was 0.9. The spectrum of the mixture is still indicative of CO-PFP. The mixture was concentrated on an Amicon,
25 PM-30 membrane (no color in filtrate) and then passed through a Sephadex G-25 column. The spectrum of the fractions that contain HSA is shown in Figure 4, spectrum 1. It is evident that a CO-PFP-HSA complex has formed and that the complex is stable (i.e.,
30 remains in the reduced state in aqueous solution). Removal of CO through illumination of the sample with bright light, in a tonometer filled with oxygen, results in a O_2 -PFP-HSA complex (spectrum 2). The oxygen can be removed by nitrogen (spectrum 3). The
35 PFP/HSA ratio after Sephadex was 0.65.

7. EXAMPLE: ABSORPTION SPECTRA OF OXYGEN BINDING BY
THE HSA-PFP COMPLEX #1

A 5 μM PFP-CO/HSA complex was prepared in 50 mM
5 Bis-Tris pH 7.0. This solution was then pipetted into
a tonometer, treated with N_2 , and rotated in a water
bath at 25°C for 10 minutes under a lamp to allow for
equilibration. This was followed by the addition of 1
10 ml of O_2 (5.75 μM) and subsequent equilibration for 5
minutes as above except in the absence of the lamp.
The oxygen titrations were monitored
spectrophotometrically and resulted in Figure 5.

The family of curves shown in Figure 5 show
varying degrees of saturation of HSA-PFP #1 as a
15 function of oxygen concentration. Although the shape
and position of the absorption peaks differ from those
of hemoglobin, the family of spectra seen in Figure 5
are qualitatively the same as one would see in an
oxygen equilibrium experiment done with hemoglobin.

20

8. EXAMPLE: OXYGEN BINDING OF HSA-PFP #1

The P_{50} for HSA-PFP #1 and human Hemoglobin A
(HbA) were determined by tonometry (Riggs and Wolbach,
25 1956, J. Gen. Physiol. 39:585-605). Specifically, a
HSA-PFP solution was placed in a gas-tight vessel
which has an attached spectrophotometer cell. The
solution was deoxygenated by a series of repeated
vacuum evacuations followed by nitrogen purges. After
30 the deoxygenated state was obtained, a "deoxy"
spectrum was obtained. Next, a series of metered
oxygen additions were made with a spectrum taken after
each addition yielding a set of curves from which can
be calculated (using established extinction
35 coefficients) the degree of saturation of the heme
sites with oxygen as a function of the oxygen partial

pressure (Figure 6). The percent oxygen saturation of human HbA and HSA-PFP #1 as a function of oxygen concentration is shown. The oxygen affinity (P_{50}) of HbA is high (2 mm Hg) relative to that of HSA-PFP #1 (10 mm Hg). This data is transformed into the Hill plot shown in Figure 7. The degree of cooperativity of HbA is high ($n_{50} = 2.7$) relative to that of HSA-PFP #1 ($n_{50} = 1.6$).

10 9. EXAMPLE: OXYGENATION CYCLES FOR HSA-PFP #2

HSA-PFP #2 was deoxygenated in a tonometer as described in Example 7. A deoxy spectrum was obtained. The oxygenated form of the molecule was obtained by adding pure O_2 to the tonometer. The oxygen spectrum was obtained.

Figure 8 (a-d) show four successive cycles of deoxygenation/oxygenation. The decrease in the difference spectra for 8(a-d) can be attributed to autooxidation of the Fe^{2+} to Fe^{3+} in the HSA-PFP #2 complex. The Fe^{3+} derivative cannot bind oxygen.

10. EXAMPLE: VASOACTIVITY EXPERIMENT FOR HSA-PFP #1

Male Wistar rats (300-400 g) were euthanized by intraperitoneal injection of sodium pentobarbital (50 mg/kg). The thoracic aortas were excised and stored in cold modified Krebs-Ringer solution containing NaCl 118.3 mM, KCl 4.7 mM, $MgSO_4$ 1.2 mM, KH_2PO_4 1.2 mM, $CaCl_2$ 2.5 mM, $NaHCO_3$ 25 mM, Ca EDTA 16 μ M, and glucose 11.1 mM (control solution). Arteries were cleared of fat and connective tissue and cut into rings. For some experiments the endothelium was removed mechanically by placing rings on filter paper wetted with the control solution, inserting the tip of a forceps into

the lumen, and rolling the ring back and forth on the filter paper. The presence of the endothelium was confirmed by determining the relaxation to acetylcholine (10^{-6} M) in arteries contracted with phenylephrine (10^{-6} M). The rings were placed in 24-well multiwell plates with Dulbecco's Modified Eagle's Medium and Ham's F-12 Medium (DMEM/F12) (1ml), in the presence or absence of endotoxin (LPS) 200 ng/ml, for 4 hours. After incubation, the rings were suspended in organ chambers containing 10 ml of control solution (37° C, pH 7.4) and aerated with 95% O_2 and 5% CO_2 . Rings were stretched progressively to 2.5 to 3 g of tension. Changes in isometric tension were recorded with a force transducer connected to an analog-to-digital input board (Scientific Solutions, Inc., Solon, OH) in an IBM 386/30 MHz personal computer. The aortic rings were rinsed three times with warm control solution, rested for 30 minutes, and the incubated with bovine cell-free Hgb, Heme-HSA, or HSA-PFP for 5 minutes before a concentration-contraction curve to phenylephrine (10^{-9} to 10^{-5} M) was obtained.

Figure 9 shows that the HSA-PFP #1 at 5 mg/ml had no significant effect on phenylephrine-evoked contraction of rat aortic rings treated with endotoxin.

The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Various publications are cited herein, the disclosures of which are incorporated by reference in their entireties.

5

10

15

20

25

30

35


WHAT IS CLAIMED IS:

1. A complex of human serum albumin and
5 porphyrin, which reversibly binds oxygen.
2. The complex of claim 1 which is
substantially not vasoactive, as detected in an in
vitro assay.
- 10 3. The complex of claim 1 in which the
porphyrin is a picket fence porphyrin.
4. The complex of claim 1 in which the picket-
15 fence porphyrin is Fe meso-tetra (a,a,a,a-pivalamido-
phenyl) porphine.
5. The complex of claim 1 in which the picket-
fence porphyrin is Fe meso-tetra (a,a,a,o-pivalamido-
20 phenyl) porphine.
6. The complex of claim 1 in which the picket-
fence porphyrin is

25

30

35



SUBSTITUTE SHEET (RULE 26)

wherein

M is Co, Fe, or Mn;

R¹ is C(CH₃)₃, or (CH₂)_nC₆H₄R²;

5 R² is H, CN, NO₂, CO-phenyl, halogen, CF₃, NHCOR³,
CO₂R³, OR³, SO₂N(R³)₂, NR⁴R⁵, or SO₂R⁶;

R³ is H, C₁-C₆ alkyl or phenyl;

R⁴ and R⁵, independently are H or C₁-C₄ alkyl;

R⁶ is C₁-C₆ alkyl or phenyl; and

n is 0-8.

10

7. A pharmaceutical composition for use as a blood substitute and blood plasma expander comprising a therapeutically effective amount of the complex of claim 1; and a pharmaceutically acceptable carrier.

15

8. A pharmaceutical composition for use as a blood substitute and blood plasma expander comprising a therapeutically effective amount of the complex of claim 2; and a pharmaceutically acceptable carrier.

20

9. A pharmaceutical composition for use as a blood substitute and blood plasma expander comprising a therapeutically effective amount of the complex of claim 3; and a pharmaceutically acceptable carrier.

25

10. A pharmaceutical composition for use as a blood substitute and blood plasma expander comprising a therapeutically effective amount of the complex of claim 4; and a pharmaceutically acceptable carrier.

30

11. A pharmaceutical composition for use as a blood substitute and blood plasma expander comprising a therapeutically effective amount of the complex of claim 5; and a pharmaceutically acceptable carrier.

35

12. A pharmaceutical composition for use as a blood substitute and blood plasma expander comprising a therapeutically effective amount of the complex of claim 6; and a pharmaceutically acceptable carrier.

5

13. A method for replacing or increasing the circulating blood volume or increasing oxygen delivery to tissues in a mammal comprising administering to said mammal the complex of claim 1.

10

14. A method for replacing or increasing the circulating blood volume or increasing oxygen delivery to tissues in a mammal comprising administering to said mammal the complex of claim 2.

15

15. A method for replacing or increasing the circulating blood volume or increasing oxygen delivery to tissues in a mammal comprising administering to said mammal the complex of claim 3.

20

16. A method for replacing or increasing the circulating blood volume or increasing oxygen delivery to tissues in a mammal comprising administering to said mammal the complex of claim 4.

25

17. A method for replacing or increasing the circulating blood volume or increasing oxygen delivery to tissues in a mammal comprising administering to said mammal the complex of claim 5.

30

18. A method for replacing or increasing the circulating blood volume or increasing oxygen delivery to tissues in a mammal comprising administering to said mammal the complex of claim 6.

35

- 25 -

19. A method for producing a complex of human serum albumin and porphyrin which reversibly binds oxygen, comprising:

- 5 a) mixing a porphyrin compound with CO to form a CO-porphyrin complex;
- b) reacting the CO-porphyrin complex with human serum albumin to yield the CO-porphyrin-human serum albumin complex;
- 10 c) removing the CO by illumination of the complex in a tonometer filled with oxygen;
- d) removing the oxygen with a nitrogen purge; and
- e) recovering the human serum albumin-porphyrin complex.

15

20. A method for producing a complex of human serum albumin and porphyrin which reversibly binds oxygen, comprising incubating a picket-fence porphyrin with human serum albumin under conditions such that a
20 complex of picket-fence porphyrin and human serum albumin forms.

25

30

35

1/9




FIG.1

SUBSTITUTE SHEET (RULE 26)

2/9




FIG.2

SUBSTITUTE SHEET (RULE 26)




FIG.3




FIG.4




FIG. 5

SUBSTITUTE SHEET (RULE 26)




FIG.6




FIG. 7

7/9




FIG.8a




FIG.8b




FIG.8c




FIG.8d

9/9




FIG.9

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/08479

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C07K 1/32, 14/765
US CL :530/409; 540/145

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 530/409; 540/145

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
CAS ONLINE, APS, EMBASE, MEDLINE, WPIDS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	ANALYTICA CHIMICA ACTA, Vol. 300, No. 1-3, issued January 1995, Tie et al., "Peroxidatic activity of metalloporphyrin binding to serum albumin: enhancement effect of serum albumin on metalloporphyrin catalyzed luminol chemiluminescence reaction", pages 215-220, see whole document.	1, 2
Y	CHEMISTRY LETTERS, issued 1991, Sagawa et al., "Stereoselective Dioxygenolysis of a Tryptophan Derivative Catalyzed by a Manganese Porphyrin bound to Bovine Serum Albumin", pages 2083-2086, see whole document.	1, 2

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
* "A" document defining the general state of the art which is not considered to be part of particular relevance	* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "E" earlier document published on or after the international filing date	* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* "A" document member of the same patent family
* "O" document referring to an oral disclosure, use, exhibition or other means	
* "P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

28 SEPTEMBER 1995

Date of mailing of the international search report

19 OCT 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

C. SAYALA

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/08479

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Biochem. J., Volume 270, issued March 1990, Cohen et al., "Binding of porphyrin to human serum albumin ", pages 325-330, see whole document.	1-20
Y	J. Amer. Chem. Soc., Volume 97, issued 1975, Collman et al., "'Picket Fence porphyrins", Synthetic Models for Oxygen Binding Hemoproteins", pages 1427-1439, see whole document.	1-20
Y	CRC Crit. Rev. Therapeutic Drug Carrier Systems, Volume 3, ISSUE 1, issued 1986, Dellacherie et al., "Synthetic Carriers of Oxygen", pages 41-94, see whole document.	1-20